CA2998390A1 - Adjuvants a base d'aluminium pour une vaccination tolerogene - Google Patents

Adjuvants a base d'aluminium pour une vaccination tolerogene Download PDF

Info

Publication number
CA2998390A1
CA2998390A1 CA2998390A CA2998390A CA2998390A1 CA 2998390 A1 CA2998390 A1 CA 2998390A1 CA 2998390 A CA2998390 A CA 2998390A CA 2998390 A CA2998390 A CA 2998390A CA 2998390 A1 CA2998390 A1 CA 2998390A1
Authority
CA
Canada
Prior art keywords
ifn
mog
myelin
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2998390A
Other languages
English (en)
Inventor
Mark D. Mannie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Publication of CA2998390A1 publication Critical patent/CA2998390A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes destinées à moduler un trouble immunologique ou une réponse immunitaire. Les méthodes comprennent l'administration à un sujet ou à une cellule d'une quantité efficace d'un antigène auto-immun et d'une cytokine anti-inflammatoire incorporés à un véhicule à base d'aluminium. Des compositions comprenant un antigène auto-immun et une cytokine anti-inflammatoire incorporés à un véhicule à base d'aluminium sont en outre décrites.
CA2998390A 2015-09-28 2016-09-28 Adjuvants a base d'aluminium pour une vaccination tolerogene Pending CA2998390A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233608P 2015-09-28 2015-09-28
US62/233,608 2015-09-28
PCT/US2016/054192 WO2017058923A1 (fr) 2015-09-28 2016-09-28 Adjuvants à base d'aluminium pour une vaccination tolérogène

Publications (1)

Publication Number Publication Date
CA2998390A1 true CA2998390A1 (fr) 2017-04-06

Family

ID=58424565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998390A Pending CA2998390A1 (fr) 2015-09-28 2016-09-28 Adjuvants a base d'aluminium pour une vaccination tolerogene

Country Status (4)

Country Link
US (2) US10940200B2 (fr)
EP (1) EP3355910A4 (fr)
CA (1) CA2998390A1 (fr)
WO (1) WO2017058923A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433139B2 (en) 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4701416A (en) 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
US20020076412A1 (en) * 1987-08-17 2002-06-20 Lawrence Steinman Methods for modulating the immune system
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
EP0702516A4 (fr) 1993-06-01 1998-04-22 Life Technologies Inc Immunisation genetique a l'aide de lipides cationiques
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5837816A (en) 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US5981221A (en) 1997-03-26 1999-11-09 Incyte Pharmaceuticals, Inc. Histone fusion protein
DE19732056A1 (de) 1997-07-25 1999-01-28 Schuler Pressen Gmbh & Co Vakuumsystem für ein Transfersystem
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6326175B1 (en) 1999-07-13 2001-12-04 Incyte Pharmaceuticals, Inc. Methods and compositions for producing full length cDNA libraries
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
JP2008505130A (ja) 2004-07-01 2008-02-21 ケベンハウンス・ウニヴェルジテート レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法
EP2572734B1 (fr) * 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
WO2010056143A1 (fr) 2008-11-13 2010-05-20 Instituto De Medicina Molecular Utilisation d'un adjuvant pour faciliter l'induction d'une tolérance immunitaire
US20120082644A1 (en) * 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
EP2461828B1 (fr) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programmation de cellules à des fins de thérapie tolérogénique
EP2670847B1 (fr) * 2011-02-03 2016-10-05 XOMA Technology Ltd. Procédés et matériaux pour améliorer l'expression d'une protéine fonctionnelle dans des bactéries
CA2839811A1 (fr) * 2011-06-23 2012-12-27 University Of Florida Research Foundation, Inc. Materiaux et procedes de modulation de reactions immunitaires

Also Published As

Publication number Publication date
EP3355910A1 (fr) 2018-08-08
WO2017058923A1 (fr) 2017-04-06
US20180280498A1 (en) 2018-10-04
US20210252137A1 (en) 2021-08-19
US10940200B2 (en) 2021-03-09
EP3355910A4 (fr) 2019-08-28

Similar Documents

Publication Publication Date Title
US10273284B2 (en) Cytokine-based fusion proteins for treatment of immune disorders
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
EP1292621B1 (fr) Compositions pour le traitement des maladies auto-immunes
Wang et al. IFN-β facilitates neuroantigen-dependent induction of CD25+ FOXP3+ regulatory T cells that suppress experimental autoimmune encephalomyelitis
US20210252137A1 (en) Aluminum based adjuvants for tolerogenic vaccination
Macri et al. Regulation of dendritic cell function by Fc-γ-receptors and the neonatal Fc receptor
EP1093464A2 (fr) Composes, compositions et procedes destines a la presentation endocytique de facteurs immunosuppresseurs
WO2019034862A1 (fr) Méthode
WO2017075037A1 (fr) Facteurs de croissance amorcés et leurs utilisations
US9610326B2 (en) Amyloid beta peptides as therapy for multiple sclerosis
WO2023235886A2 (fr) Induction de tolérance à l'antigène par utilisation de variants flt3l
Moorman A Single-Chain Gmcsf-Mog Tolerogenic Vaccine Expands Mog-Specific CD25+ FOXP3+ Regulatory T Cells through Low-Efficiency Antigen Recognition Events to Inhibit Experimental Autoimmune Encephalomyelitis
CN114641304A (zh) 改良的疫苗制剂
WO2019246408A2 (fr) Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1
US20130337044A1 (en) Modulation of effector t cell responses by local depletion of complement component c3
Rynda Low dose tolerance vaccine platform, reovirus protein sigma 1 and treatment of autoimmunity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817

EEER Examination request

Effective date: 20210817